New antibody combo tackles tough leukemia
NCT ID NCT06648889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug isatuximab to standard chemotherapy can help adults with T-cell acute lymphoblastic leukemia (T-ALL) that has relapsed or not responded to treatment. The study enrolls 40 people in two groups: one for those with a full relapse and one for those with minimal residual disease. Researchers will measure how many patients achieve complete remission and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isatuximab (a targeted antibody) given with chemotherapy
- What this could lead to
- If successful, this could offer a new treatment option for patients with T-ALL that has come back or not responded to standard therapy.
- What could go wrong
- This is a small, early-phase trial (40 people) without a comparison group, so results may not apply broadly. Side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt Hämatologie
RECRUITINGBerlin, 12203, Germany
Contact
Contact
-
Gesundheit Nord Klinikverbund Bremen gGmbH, Klinikum Bremen-Mitte, Med. Klinik I
RECRUITINGBremen, 28205, Germany
Contact
Contact
-
Goethe University Hospital Frankfurt, Department of Medicine, Hematology and Oncology
RECRUITINGFrankfurt am Main, 60580, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I
RECRUITINGDresden, 01307, Germany
Contact
Contact
-
Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin - Onkologie und Hämatologie
RECRUITINGOldenburg, 26135, Germany
Contact
Contact
-
Robert-Bosch-Krankenhaus; Abteilung für Hämatologie, Onkologie und Palliativmedizin
RECRUITINGStuttgart, 70376, Germany
Contact
Contact
-
University Hospital Augsburg, II. Medizinischen Klinik, Hämatologie, internistische Onkologie und Hämostaseologie
RECRUITINGAugsburg, 86156, Germany
Contact
Contact
-
University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology
RECRUITINGDüsseldorf, 40225, Germany
Contact
Contact
-
University Hospital Erlangen AöR, Department of Medicine 5
RECRUITINGErlangen, 91054, Germany
Contact
Contact
-
University Hospital Hamburg-Eppendorf, Department of Medicine II
RECRUITINGHamburg, 20251, Germany
Contact
Contact
-
University Hospital Heidelberg, Department V, Hematology, Oncology and Rheumatology
RECRUITINGHeidelberg, 69120, Germany
Contact
Contact
-
University Hospital Leipzig; Klinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Bereich Hämatologie und Zelltherapie
RECRUITINGLeipzig, 04103, Germany
Contact
Contact
-
University Hospital München-Großhadern, Medizinische Klinik und Poliklinik III
RECRUITINGMünchen, 81377, Germany
Contact
Contact
-
University Hospital Münster, Medizinische Klinik A / KMT-Zentrum
RECRUITINGMünster, 48149, Germany
Contact
Contact
-
University Hospital Schleswig-Holstein, Campus Kiel, Medical Department II
RECRUITINGKiel, 24105, Germany
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.